CAMBRIDGE, Mass., April 03, 2017 (GLOBE NEWSWIRE) — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, reported non-clinical and clinical data for its GITR agonist antibody, TRX518, and its Dickkopf-1 inhibitor antibody, DKN-01, at the 2017 American Association for Cancer Research (AACR) Annual Meeting. TRX518 Data Presentation, Abstract Number: CT018 Roberta ...
The post Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 and DKN-01 at the 2017 AACR Annual Meeting appeared first on ForexTV.
April 03, 2017 at 04:09PM
http://ift.tt/2oPYe5o
from Nasdaq NewsFeed
http://ift.tt/2oPYe5o
No comments:
Post a Comment